{"name":"InxMed (Shanghai) Co., Ltd.","slug":"inxmed-shanghai-co-ltd","ticker":"","exchange":"","domain":"inxmedshanghai.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IN10018 in combination with D-1553","genericName":"IN10018 in combination with D-1553","slug":"in10018-in-combination-with-d-1553","indication":"Advanced or metastatic solid tumors (indication under phase 3 investigation)","status":"phase_3"}]}],"pipeline":[{"name":"IN10018 in combination with D-1553","genericName":"IN10018 in combination with D-1553","slug":"in10018-in-combination-with-d-1553","phase":"phase_3","mechanism":"IN10018 in combination with D-1553 represents a dual-targeted immunotherapy approach designed to enhance anti-tumor immune responses through complementary mechanisms.","indications":["Advanced or metastatic solid tumors (indication under phase 3 investigation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQV0NXQ1d1RWNJUU9HTlBzb1RqbDJfSFRtRnRWSndLeXpnQVBQRkUySTAyaWdlUjB3U2tpcTB1d3VjMjRvU3hTUTB3b2NhRWJaeE9OS1k5WkFUMURyZ1hyOU9fNnFDYVY3MWtxRlloRFEzclBsRURpUEY3R1FGaS0ydHZvVllpZ3VJYk9WYlI2RE1kWU9hR1ZtU0c0cXF1R2JLbzYweVJvemtwVkNMUmIwVFEzaklpLXdyR05HVnprcUtvZw?oc=5","date":"2026-03-31","type":"deal","source":"The Standard (HK)","summary":"HKSTP biotech pipeline moves towards listings amid strong deal flow - The Standard (HK)","headline":"HKSTP biotech pipeline moves towards listings amid strong deal flow - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"PR Newswire","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - PR Newswire","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQT195Um84VEw5TDFnZ0x5N0VydUJ0aDNTVGF1SDVWdjh0bEFwbEtyZzM4R2ZEbENDdTVwQzJSV0ZrUU9JSlVZbTZ5TXlYd3NyYmpXT3pVMzdEUHRuTi1lYURucmpkR2M4bzJTeTFNU05iM3dIX0JNNzdoT1otUWVoT3VZamZrTzA5bmYxaUxmTEMxZVpuWm5aRFlVdmZWeXRxU2lWclBRLXg0eEZndGl6VkxBUGRYWjFHdHp0bU9jdnQ1SmpfLXlOd3dPTkhSMTJPRHdDZlpfMjdHQjNyR21Zd2pnU21aQTNOam1SZUw5ZkNyb19xOUMyc0pxRnl4Z2hnRHdLc19CTkdQSy1EYTdDTFRuYkZYRHE0S2tFYm1TMVI?oc=5","date":"2025-10-14","type":"trial","source":"GlobeNewswire","summary":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma - GlobeNewswire","headline":"Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"PR Newswire","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}